We’re thrilled to welcome three worldclass leaders to the Scientific Advisory Board of Immuthera, a subsidiary of PolTREG Dr. Jay Skyler – A pioneer of intensive insulin therapy, architect of NIH trials (DPT1, TrialNet), and founding EditorinChief of Diabetes Care.Dr. Desmond Schatz – Champion of pediatric diabetes prevention and genetics (TEDDY, HIRN), with 400+ publications … Continued
Mariusz Jablonski, Chief Business Officer, and Dan Shelly, Chief Business Development Officer at PolTREG, held dozens of insightful meetings with representatives from big pharma, investment funds, physicians and leading scientists. We’re proud of the growing interest in our innovative pipeline, which includes the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, multi-edited/allogeneic CAR-Tregs, antigen-specific Tregs, … Continued
We are excited to announce that PolTREG has launched Immuthera, a wholly owned subsidiary and a U.S. C Corporation registered in Delaware. This marks an important step in expanding our presence in the American market. Immuthera will have full access to PolTREG’s extensive pipeline of cellular therapies, including polyclonal Tregs, CAR-TREGs, multi-edited/allogeneic CAR-Tregs, and antigen-specific … Continued
Join us for the PolTREG Q1 2025 financial results webinar! We are pleased to invite you to our upcoming webinar, which will present the financial results for Q1 2025 and PolTREG’s development plans. Join us on Friday, May 16 at 1:00 PM CEST, where you will hear directly from our company’s management: • Piotr Trzonkowski, Co-founder and CEO • … Continued
Thanks to a non-refundable grant of PLN 6.4 million (USD 1.7 million) awarded by the Medical Research Agency (Agencja Badań Medycznych), PolTREG will carry out preclinical studies of its antigen-specific regulatory Treg project by the end of Q1 2026. This therapy represents a new generation of Tregs, designed to selectively and precisely suppress undesired immune … Continued
We’re excited to announce our new partnership with Kubera N.A. LLC, headquartered in New York. Under this agreement, Kubera will support PolTREG S.A. in securing U.S. financing on terms optimized for our growth. This collaboration runs in parallel and synergy with our recently signed agreement with Noble Capital Markets Inc. Over the past few years, … Continued
We are pleased to announce our partnership with Noble Capital Markets Inc., a U.S. investment bank with extensive expertise in biotech financing. This collaboration aligns with PolTREG’s strategic plans for growth in the United States. “PolTREG is financially stable, with secured funding for our priority projects in the coming quarters. Over the years, we have … Continued
We are excited to invite you to our upcoming webinar, co-organized with Strefa Inwestorów. PolTREG has recently established a synergistic collaboration with the Swiss company Antion Biosciences, aimed at developing and commercializing next-generation allogeneic “off-the-shelf” CAR-Treg therapies with enhanced immunomodulatory activity. The objectives and opportunities arising from this project will be presented during the webinar. … Continued
We are proud to announce our collaboration with Antion Biosciences, a Swiss biotechnology company at the forefront of gene silencing technology, to develop next-generation cell therapies that have the potential to transform the treatment landscape for patients worldwide. The expected results of the cooperation will be engineered allogeneic off-the-shelf CAR-Tregs products with enhanced immunomodulatory activity … Continued
We are excited to announce our collaboration with Kinexum, a significant step in intensifying PolTREG’s presence in the U.S. As part of this partnership, we will jointly prepare and conduct a pre-IND meeting with the FDA. This meeting will provide an opportunity to present our research findings and the proposed clinical trial protocol for TREGS … Continued